Last reviewed · How we verify
CAZ/AVI
CAZ/AVI is a combination of ceftazidime (a third-generation cephalosporin) and avibactam (a beta-lactamase inhibitor) that works together to overcome bacterial resistance and kill susceptible gram-negative and gram-positive bacteria.
CAZ/AVI is a combination of ceftazidime (a third-generation cephalosporin) and avibactam (a beta-lactamase inhibitor) that works together to overcome bacterial resistance and kill susceptible gram-negative and gram-positive bacteria. Used for Complicated intra-abdominal infections, Complicated urinary tract infections, Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
At a glance
| Generic name | CAZ/AVI |
|---|---|
| Also known as | Continous group, Intermittent group |
| Sponsor | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
| Drug class | Beta-lactam/beta-lactamase inhibitor combination |
| Target | Bacterial penicillin-binding proteins (PBPs); serine beta-lactamases |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Ceftazidime is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Avibactam is a non-beta-lactam beta-lactamase inhibitor that protects ceftazidime from degradation by serine beta-lactamases, including extended-spectrum beta-lactamases (ESBLs), AmpC beta-lactamases, and some carbapenemases, thereby restoring ceftazidime's antibacterial activity against resistant organisms.
Approved indications
- Complicated intra-abdominal infections
- Complicated urinary tract infections
- Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia
- Gram-negative infections including those caused by extended-spectrum beta-lactamase (ESBL) and AmpC beta-lactamase producing organisms
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Headache
- Phlebitis at infusion site
Key clinical trials
- Different Administration Regimens of CAZ-AVI in Combination With ATM for the Treatment of CR-GNB (PHASE4)
- PK/PD Relationship of CAZ/AVI and FOS in the Treatment of Patients With Infections Due to CRE
- A Combination Therapy With Ceftazidime and Fosfomycin Will be Compared to Ceftazidime Alone in Hospitalized Adult Patients With Suspected Severe Gram-negative Bacterial Infections (PHASE3)
- Real-World Study of Ceftazidime Avibactam in China
- Clinical Study on Monitoring the Plasma Concentration of Ceftazidime-Avibactam in Critically Ill Patients
- A Multicenter Clinical Study on the Continuous vs. Intermittent Infusion of Ceftazidime-Avibactam in Critically Ill Patients With Severe Infections (PHASE4)
- Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults (PHASE4)
- PK/PD Analysis of Ceftazidime/Avibactam or Cefiderocol With or Without Fosfomycin for the Treatment of Difficult To-treat Gram-negative Infections
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CAZ/AVI CI brief — competitive landscape report
- CAZ/AVI updates RSS · CI watch RSS
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School portfolio CI